Alteogen
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Alteogen is a South Korean biotechnology company that develops drug technologies and biologic medicines.
It is best known for a platform that converts medicines given by intravenous infusion into versions that can be given as a quick under-the-skin injection, which it licenses to global drugmakers. The company also develops biosimilars and its own novel treatments. It earns money largely through licensing deals and related milestone payments.
Summary is AI-generated and may contain errors · figures from DART filings
Much of its value rests on licensing its injection-technology platform to large pharmaceutical companies.
Alteogen in five facts
What does Alteogen do?
Alteogen is a South Korean biotechnology company that develops drug technologies and biologic medicines.
Where is Alteogen listed and in which sector?
Alteogen (Korean name: 알테오젠) trades under KRX code 196170 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Alteogen?
Its market capitalisation was US$12.6B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Alteogen's latest annual revenue and operating profit?
For fiscal year 2025, Alteogen reported revenue of US$162.9M, operating profit of US$80.7M and net income of US$109.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 109.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Securities registration statement (merger)Oct 19
- Securities issuance results (voluntary)Oct 14
- Securities issuance results (voluntary)Oct 14
- Securities registration statement (merger)Oct 14
- Investor relations (IR) meetingOct 8
- Shareholder register closure / record date setOct 6
- Merger decision (subsidiary)M&A · Oct 6
- Material event report (merger)M&A · Oct 6
- Material event report (rights offering)
Alteogen disclosed convertible bonds to raise US$37.4M, about 0.3% of its market value.
Capital raise · Oct 6 - Material event report (rights offering)
Alteogen disclosed convertible bonds to raise US$37.4M, about 0.3% of its market value.
Capital raise · Oct 6 - Material event report (rights offering)
Alteogen disclosed convertible bonds to raise US$37.4M, about 0.3% of its market value.
Capital raise · Oct 6 - Material event report (rights offering)
Alteogen disclosed convertible bonds to raise US$37.4M, about 0.3% of its market value.
Capital raise · Oct 6 - Investor relations (IR) meetingSep 21
- Material management matter relevant to investment decisionsSep 2
- Material management matter relevant to investment decisionsAug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
Alteogen filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$48.4M (+269.5% year on year), operating profit of US$24M (from a loss a year earlier) and net income of US$21.1M (from a loss a year earlier).
Earnings · Aug 7 - Ex-rights (bonus issue)
Alteogen Co., Ltd. common shares (code A196170) will go ex-rights on August 5, 2026 at a base price of US$186.92, following a bonus share issue.
Capital raise · Aug 4 - [Amended] Material event report (bonus issue)
Alteogen Inc. amended its July 16, 2026 bonus-issue disclosure to push the expected listing date for the new shares from August 20 to August 26, 2026; the bonus issue allots 0.3 new shares per existing share, issuing 16,068,790 common shares and 122,037 preferred shares, with a record date of August 6, 2026.
Capital raise · Jul 20 · 2 versions - Trading suspension (bonus issue)
Alteogen's common shares were suspended from trading from 15:31:00 on 2026-07-16 due to a bonus share issue, with the suspension lasting until market close; related futures and options, if listed, are suspended simultaneously.
Capital raise · Jul 16 - Operating results (consolidated) (preliminary) (fair disclosure)
Alteogen filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$49.2M (−14.5% year on year), operating profit of US$27M (−35.6% year on year) and net income of US$49M (−14.1% year on year).
Earnings · May 8 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Alteogen reported consolidated results for FY2025: revenue of US$151M (+109.8% year on year), operating profit of US$74.6M (+320.8% year on year) and net income of US$101M (+137.8% year on year).
Earnings · Feb 27 - Cash/in-kind dividend decision
Alteogen declared a cash dividend of US$0.25 per share.
Dividend · Feb 11 - Operating results (preliminary) (fair disclosure)
Alteogen filed provisional (unaudited) separate results for FY2025: revenue of US$140M and operating profit of US$79.2M.
Earnings · Feb 2